1
|
Montoro J, Pomares H, Villacampa G, Merchán B, Molero A, Alonso E, Gallur L, Grau J, Salamero O, Roldán E, Saumell S, Ortega M, Sureda A, Bosch F, Arnan M, Valcárcel D. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. Leuk Lymphoma 2018; 60:1522-1527. [PMID: 30499738 DOI: 10.1080/10428194.2018.1542151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
In clinical practice, patients with myelodysplastic syndromes (MDS) are usually classified in low or high-risk groups to take therapeutic decisions, conservative for low-risk, whereas active for high-risk. Nevertheless, in the Revised International Prognostic Scoring System (IPSS-R) is not well stated which patients are low or high-risk. This study was aimed to ascertain in 364 MDS patients which IPSS-R threshold better dichotomized in low vs. high-risk. The best dichotomization was obtained with an IPSS-R cut-point of 3. Accordingly, 68% patients were classified as low-risk (median OS, 61.3 months) and 32% as high-risk MDS (median OS, 13.9 months) (p < .001). Interestingly, the intermediate IPSS-R risk patients presented an OS more related to the high IPSS-R than to the low IPSS-R risk group. In conclusion, an IPSS-R cut-point of 3 led to a meaningful stratification in low and high-risk that can be helpful for the clinical management of MDS patients.
Collapse
Affiliation(s)
- Julia Montoro
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Helena Pomares
- c Department of Hematology , Institut Català d'Oncologia (ICO) - Hospitalet , Barcelona , Spain
| | - Guillermo Villacampa
- d Oncology Data Science (ODysSey) Group , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Brayan Merchán
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Antonieta Molero
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Esther Alonso
- e Department of Pathology , Hospital Universitari de Bellvitge , Barcelona , Spain Hospitalet
| | - Laura Gallur
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Javier Grau
- f Department of Laboratory Hematology , University Hospital Germans Trias i Pujol, Badalona, Spain. ICO Josep Carreras Leukemia Research Institute , Badalona , Spain
| | - Olga Salamero
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Elisa Roldán
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Silvia Saumell
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Margarita Ortega
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Anna Sureda
- c Department of Hematology , Institut Català d'Oncologia (ICO) - Hospitalet , Barcelona , Spain
| | - Francesc Bosch
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| | - Montserrat Arnan
- c Department of Hematology , Institut Català d'Oncologia (ICO) - Hospitalet , Barcelona , Spain
| | - David Valcárcel
- a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.,b Experimental Hematology Unit , Vall d'Hebron Institute of Oncology (VHIO) , Barcelona , Spain
| |
Collapse
|
2
|
Ridgeway JA, Tinsley S, Kurtin SE. Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes. J Adv Pract Oncol 2017; 8:29-39. [PMID: 29900015 PMCID: PMC5995536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Myelodysplastic syndromes (MDS) comprise a group of diverse clonal hematopoietic stem cell malignancies that are characterized by ineffective hematopoiesis and progressive bone marrow failure. Clinical symptoms are generally nonspecific. The diagnosis, classification, and risk stratification of MDS rely on the evaluation of peripheral blood and bone marrow sampling using the Revised International Prognostic Scoring System tool. Accurate diagnosis and risk stratification require a good-quality bone marrow sample. Bone marrow samples are obtained using two complementary techniques: bone marrow aspiration and bone marrow biopsy. Knowledge of what constitutes an adequate bone marrow sample and a proper bone marrow sampling technique may help advanced practitioners obtain quality samples while minimizing patient discomfort and risk. Patient preparation and positioning, site selection, sampling equipment, and sampling technique can help lead to the collection of high-quality bone marrow samples. Postprocedural care and knowledge of potential complications can reduce a patient's pain and optimize recovery.
Collapse
Affiliation(s)
| | - Sara Tinsley
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
| | | |
Collapse
|
3
|
Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. Br J Haematol 2016; 175:975-979. [DOI: 10.1111/bjh.13902] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Emmanuel Gyan
- Service d'hématologie et thérapie cellulaire; CHU de Tours; Tours France
- Faculté de Médecine; Université François-Rabelais; UMR CNRS 7292; Tours France
| | - Valérie Andrieu
- Département Hématologie et Immunologie; Hôpital Bichat; Assistance Publique-Hôpitaux de Paris (AP-HP); Paris 7 University; Paris France
| | - Alessandro Sanna
- Unità Funzionale di Ematologia; Università degli Studi di Firenze; AOU Careggi; Florence Italy
| | - Agnès Caille
- INSERM; CIC 1415; Tours France
- Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- CHU de Tours; Tours France
| | - Jennifer Schemenau
- Department of Haematology, Oncology and Clinical Immunology; Medical Faculty; University of Düsseldorf; Düsseldorf Germany
| | - Isabelle Sudaka
- Laboratoire d'hématologie; CHU de Nice; Hospital Cimiez; Nice France
| | - Virginie Siguret
- Hématologie biologique - Hémostase - Thrombose; Hôpital Lariboisière; INSERM UMR-S-1140; AP-HP; Paris France
| | - Michèle Malet
- Service d'hématologie biologique; CHU de Caen; Caen France
| | - Sophie Park
- Service d'hématologie; Centre Hospitalier Universitaire; Grenoble France
| | | | - Jacques Mairesse
- Clinique Saint Pierre d'Ottignies; Service de Biopathologie; Ottignies Belgium
| | | | - Stéphane Cheze
- Service d'hématologie; Centre Hospitalier Universitaire; Caen France
| | - Odile Beyne-Rauzy
- Service de Médecine Interne; Centre hospitalier universitaire; Toulouse France
| | - Marie Sébert
- Service d'Hématologie clinique; Hôpital Saint-Louis; Assistance Publique Hôpitaux de Paris (APHP); Paris 7 University; Paris France
| | - Rosa Sapena
- Groupe Francophone des Myélodysplasies; Hôpital Saint-Louis; AP-HP; Paris France
| | - Hacene Zerazhi
- Service d'onco-hématologie; Centre Hospitalier; Avignon France
| | - Laurence Legros
- Service d'hématologie clinique; Centre Hospitalier Universitaire; Nice France
| | | | - Shanti Natarjan Amé
- Département d'Hématologie et d'Oncologie; Centre Hospitalier Universitaire; Strasbourg France
| | - Ulrich Germing
- Department of Haematology, Oncology and Clinical Immunology; Medical Faculty; University of Düsseldorf; Düsseldorf Germany
| | - Valeria Santini
- Unità Funzionale di Ematologia; Università degli Studi di Firenze; AOU Careggi; Florence Italy
| | - Flavia Salvi
- Haematology Unit; SS. Antonio e Biagio e Cesare Arrigo Hospital; Alessandria Italy
| | - Daniela Gioia
- Fondazione Italiana Sindromi Mielodisplastiche (FISM) Onlus; Alessandria Italy
| | - Monia Lunghi
- Haematology; AOU Maggiore della Carità; Novara Italy
| | - François Dreyfus
- Service d'hématologie; Hôpital Cochin; AP-HP; Université Paris 5; Paris France
| | - Pierre Fenaux
- Service d'Hématologie clinique; Hôpital Saint-Louis; Assistance Publique Hôpitaux de Paris (APHP); Paris 7 University; Paris France
| | | |
Collapse
|
4
|
Guezguez B, Almakadi M, Benoit YD, Shapovalova Z, Rahmig S, Fiebig-Comyn A, Casado FL, Tanasijevic B, Bresolin S, Masetti R, Doble BW, Bhatia M. GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia. Cancer Cell 2016; 29:61-74. [PMID: 26766591 DOI: 10.1016/j.ccell.2015.11.012] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Revised: 04/23/2015] [Accepted: 11/17/2015] [Indexed: 01/20/2023]
Abstract
Initial pathway alternations required for pathogenesis of human acute myeloid leukemia (AML) are poorly understood. Here we reveal that removal of glycogen synthase kinase-3α (GSK-3α) and GSK-3β dependency leads to aggressive AML. Although GSK-3α deletion alone has no effect, GSK-3β deletion in hematopoietic stem cells (HSCs) resulted in a pre-neoplastic state consistent with human myelodysplastic syndromes (MDSs). Transcriptome and functional studies reveal that each GSK-3β and GSK-3α uniquely contributes to AML by affecting Wnt/Akt/mTOR signaling and metabolism, respectively. The molecular signature of HSCs deleted for GSK-3β provided a prognostic tool for disease progression and survival of MDS patients. Our study reveals that GSK-3α- and GSK-3β-regulated pathways can be responsible for stepwise transition to MDS and subsequent AML, thereby providing potential therapeutic targets of disease evolution.
Collapse
Affiliation(s)
- Borhane Guezguez
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada
| | - Mohammed Almakadi
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada; Department of Oncology, Juravinski Cancer Center, Faculty of Health Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada
| | - Yannick D Benoit
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada
| | - Zoya Shapovalova
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada
| | - Susann Rahmig
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada
| | - Aline Fiebig-Comyn
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada
| | - Fanny L Casado
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada
| | - Borko Tanasijevic
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada
| | - Silvia Bresolin
- Department of Women's and Children's Health, University of Padova, Padua, Italy
| | - Riccardo Masetti
- Department of Pediatric Oncology and Hematology, University of Bologna, Bologna, Italy
| | - Bradley W Doble
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada
| | - Mickie Bhatia
- McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8N 3Z5, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada; McMaster Stem Cell and Cancer Research Institute (SCC-RI), Michael G. DeGroote School of Medicine, McMaster University, 1280 Main Street West, MDCL 5029, Hamilton, ON L8S 4K1, Canada.
| |
Collapse
|
5
|
Zeidan AM, Gore SD, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol 2015; 22:146-54. [PMID: 25575032 DOI: 10.1097/moh.0000000000000110] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE OF REVIEW Myelodysplastic syndromes (MDS) are characterized by significant biologic and clinical heterogeneity. Because of the wide outcome variability, accurate prognostication is vital to high-quality risk-adaptive care of MDS patients. In this review, we discuss the current state of prognostic schemes for MDS and overview efforts aimed at utilizing molecular aberrations for prognostication in clinical practice. RECENT FINDINGS Several prognostic instruments have been developed and validated with increasing accuracy and complexity. Oncologists should be aware of the inherent limitations of these prognostic tools as they counsel patients and make clinical decisions. As more therapies are becoming available for MDS, the focus of model development is shifting from prognostic to treatment-specific predictive instruments. In addition to providing additional prognostic data beyond traditional clinical and pathologic parameters, the improved understanding of the genetic landscape and pathophysiologic consequences in MDS may allow the construction of treatment-specific predictive instruments. SUMMARY How to best use the results of molecular mutation testing to inform clinical decision making in MDS is still a work in progress. Important steps in this direction include standardization in performance and interpretation of assays and better understanding of the independent prognostic importance of the recurrent mutations, especially the less frequent ones.
Collapse
Affiliation(s)
- Amer M Zeidan
- aSection of Hematology, Department of Internal Medicine, Yale University, New Haven, Connecticut bDepartment of Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
| | | | | | | |
Collapse
|
6
|
Refractory thrombocytopenia and neutropenia: a diagnostic challenge. Mediterr J Hematol Infect Dis 2015; 7:e2015018. [PMID: 25745545 PMCID: PMC4344166 DOI: 10.4084/mjhid.2015.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2014] [Accepted: 01/28/2015] [Indexed: 11/27/2022] Open
Abstract
The 2008 WHO classification identified refractory cytopenia with unilineage dysplasia (RCUD) as a composite entity encompassing refractory anemia, refractory thrombocytopenia (RT), and refractory neutropenia (RN), characterized by 10% or more dysplastic cells in the bone marrow respective lineage. The diagnosis of RT and RN is complicated by several factors. Diagnosing RT first requires exclusion of familial thrombocytopenia, chronic auto-immune thrombocytopenia, concomitant medications, viral infections, or hypersplenism. Diagnosis of RN should also be made after ruling out differential diagnoses such as ethnic or familial neutropenia, as well as acquired, drug-induced, infection-related or malignancy-related neutropenia. An accurate quantification of dysplasia should be performed in order to distinguish RT or RN from the provisional entity named idiopathic cytopenia of unknown significance (ICUS). Cytogenetic analysis, and possibly in the future somatic mutation analysis (of genes most frequently mutated in MDS), and flow cytometry analysis aberrant antigen expression on myeloid cells may help in this differential diagnosis. Importantly, we and others found that, while isolated neutropenia and thrombocytopenia are not rare in MDS, those patients can generally be classified (according to WHO 2008 classification) as refractory cytopenia with multilineage dysplasia or refractory anemia with excess blasts, while RT and RN (according to WHO 2008) are quite rare. These results suggest in particular that identification of RT and RN as distinct entities could be reconsidered in future WHO classification updates.
Collapse
|
7
|
Sotirova T, Stojanovic A, Genadieva-Stavric S, Krstevska S, Spasovski D, Balkanov T. Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes. Mater Sociomed 2014; 26:292-6. [PMID: 25568624 PMCID: PMC4272834 DOI: 10.5455/msm.2014.26.292-296] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Accepted: 10/25/2014] [Indexed: 12/13/2022] Open
Abstract
Background: Accurate prediction of a patient's prognosis is useful to define the risk posed by the disease. Age, gender, peripheral blood cytopenia, proportion of bone marrow (BM) blasts, performance status, comorbidities, transfusion dependence, specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS. Aim: to assess the influence of the some prognostic factors like age, gender, cytopenia, BM blast percentage, transfusion dependence, ferritin, hemoglobin (Hb), lactate dehydrogenase (LDH), albumin and specific karyotype abnormalities in myelodysplastic syndromes on overall survival (OS). Patients and methods: we retrospectively analyzed the cohort of 108 patients diagnosed between 1.1.2011 and 31.12.2013 at the University Clinic of Hematology, Ss Cyril and Methodius University, Skopje, Macedonia. They were evaluated for clinical and hematologic features at diagnosis and at leukemic transformation. Results: in the study group 62 were man and 46 women. Male to female ratio was 1.35 to 1. The differences in OS between men and women were significant (p = .03015). The mean age at diagnosis was 66,6 years. According to the age OS was 16,4 months. FAB subtypes influenced OS significantly (p = .03015). OS inversely correlated with BM blast percentage (p= .02327). Cytopenia had no impact on OS (p=.33755). Hb as a whole and groups with different levels of Hb had no influence on OS (p = .12142) and (p= .07535), respectively. The group with ferritin <500 µg/L had better OS (p=.04720). Transfusion dependence, LDH and albumin had no impact on OS. Leukemic transformation was noticed in 10 (9,3%) patients. Mortality was 36,1%. Conclusion: gender, FAB subtypes, BM blast percentage and the serum levels of ferritin had an influence on OS, while age, hemoglobin level, transfusion dependence, LDH and albumin had no impact on OS.
Collapse
Affiliation(s)
- Tatjana Sotirova
- University Clinic of Hematology, Ss Cyril and Methodius University, Skopje, Macedonia
| | - Aleksandar Stojanovic
- University Clinic of Hematology, Ss Cyril and Methodius University, Skopje, Macedonia
| | | | - Svetlana Krstevska
- University Clinic of Hematology, Ss Cyril and Methodius University, Skopje, Macedonia
| | - Dejan Spasovski
- University Clinic for Rheumatology, Ss Cyril and Methodius University, Skopje, Macedonia
| | - Trajan Balkanov
- Institute for Pharmacology, Ss Cyril and Methodius University, Skopje, Macedonia
| |
Collapse
|
8
|
Zeidan AM, Komrokji RS. There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep 2013; 8:351-60. [PMID: 23979829 PMCID: PMC4133773 DOI: 10.1007/s11899-013-0172-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Myelodysplastic syndromes (MDS) include a diverse group of clonal hematopoietic disorders characterized by progressive cytopenias and propensity for leukemic progression. The biologic heterogeneity that underlies MDS translates clinically in wide variations of clinical outcomes. Several prognostic schemes were developed to predict the natural course of MDS, counsel patients, and allow evidence-based, risk-adaptive implementation of therapeutic strategies. The prognostic schemes divide patients into subgroups with similar prognosis, but the extent to which the prognostic prediction applies to any individual patient is more variable. None of these instruments was designed to predict the clinical benefit in relation to any specific MDS therapy. The prognostic impact of molecular mutations is being more recognized and attempts at incorporating it into the current prognostic schemes are ongoing.
Collapse
Affiliation(s)
- Amer M Zeidan
- Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, CRB1 building, room 186, Baltimore, MD, 21287, USA,
| | | |
Collapse
|
9
|
Landolfi R, Gennaro LD. Thrombosis in myeloproliferative and myelodysplastic syndromes. Hematology 2013; 17 Suppl 1:S174-6. [DOI: 10.1179/102453312x13336169156898] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Affiliation(s)
- Raffaele Landolfi
- Institute of Internal Medicine and GeriatricsCatholic University School of Medicine, Rome, Italy
| | - Leonardo Di Gennaro
- Institute of Internal Medicine and GeriatricsCatholic University School of Medicine, Rome, Italy
| |
Collapse
|
10
|
Ono M, Tanaka RJ, Kano M, Sugiman T. Visualising the cross-level relationships between pathological and physiological processes and gene expression: analyses of haematological diseases. PLoS One 2013; 8:e53544. [PMID: 23301083 PMCID: PMC3534650 DOI: 10.1371/journal.pone.0053544] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Accepted: 12/03/2012] [Indexed: 11/18/2022] Open
Abstract
The understanding of pathological processes is based on the comparison between physiological and pathological conditions, and transcriptomic analysis has been extensively applied to various diseases for this purpose. However, the way in which the transcriptomic data of pathological cells relate to the transcriptomes of normal cellular counterparts has not been fully explored, and may provide new and unbiased insights into the mechanisms of these diseases. To achieve this, it is necessary to develop a method to simultaneously analyse components across different levels, namely genes, normal cells, and diseases. Here we propose a multidimensional method that visualises the cross-level relationships between these components at three different levels based on transcriptomic data of physiological and pathological processes, by adapting Canonical Correspondence Analysis, which was developed in ecology and sociology, to microarray data (CCA on Microarray data, CCAM). Using CCAM, we have analysed transcriptomes of haematological disorders and those of normal haematopoietic cell differentiation. First, by analysing leukaemia data, CCAM successfully visualised known relationships between leukaemia subtypes and cellular differentiation, and their characteristic genes, which confirmed the relevance of CCAM. Next, by analysing transcriptomes of myelodysplastic syndromes (MDS), we have shown that CCAM was effective in both generating and testing hypotheses. CCAM showed that among MDS patients, high-risk patients had transcriptomes that were more similar to those of both haematopoietic stem cells (HSC) and megakaryocyte-erythroid progenitors (MEP) than low-risk patients, and provided a prognostic model. Collectively, CCAM reveals hidden relationships between pathological and physiological processes and gene expression, providing meaningful clinical insights into haematological diseases, and these could not be revealed by other univariate and multivariate methods. Furthermore, CCAM was effective in identifying candidate genes that are correlated with cellular phenotypes of interest. We expect that CCAM will benefit a wide range of medical fields.
Collapse
Affiliation(s)
- Masahiro Ono
- Immunobiology Unit, Institute of Child Health, University College London, London, United Kingdom.
| | | | | | | |
Collapse
|
11
|
Triantafyllidis I, Ciobanu A, Stanca O, Lupu AR. Prognostic factors in myelodysplastic syndromes. MAEDICA 2012; 7:295-302. [PMID: 23483702 PMCID: PMC3593279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 05/27/2012] [Accepted: 09/25/2012] [Indexed: 06/01/2023]
Abstract
BACKGROUND Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cell and are characterized by ineffective hematopoiesis with normo- or hyper cellular bone marrow and cytopenia(s).The natural evolution of the disease consists of bone marrow failure (leading to infectious and hemorrhagic episodes or anemia related complications) and transformation to acute myeloid leukemia. Because MDSs display remarkable clinical, pathologic, and cytogenetic heterogeneity, with variable evolution and survival ranging from months to years, the predictive factors of prognosis have a key role in optimal therapeutic decisions.The purpose of this paper is to analyze prognostic factors within a group of patients diagnosed with myelodysplastic syndromes. The prognostic factors taken into account are: the number and depth of cytopenias, percentage of bone marrow blasts, cytogenetic abnormalities, intensity of anemia and transfusional dependence. These factors are related to overall survival, leukemia free survival, bone marrow failure complications, leukemic evolution, treatment decisions and the response to treatment. MATERIAL AND METHOD The study group comprises of 119 patients diagnosed with de novo MDS, between 2008 and 2011 in the Hematology Department of Coltea Clinical Hospital. In this monitoring period the patients were stratified according to the FAB (French-American-British) morphologic classification. RESULTS This study revealed that the outcomes of patients with MDS is influenced by the percentage of bone marrow blasts at diagnosis, the number and severity of hematopoietic lineage affected by cytopenia and by the presence of chromosomal abnormalities. CONCLUSIONS The studied prognostic factors have predictive value in terms of survival, leukemic transformation, treatment response and development of bone marrow failure-related characteristic complications.
Collapse
|
12
|
Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica 2012; 98:568-75. [PMID: 23065505 DOI: 10.3324/haematol.2012.071449] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is uncertain and its assessment was the major aim of this study. The different peripheral blood and bone marrow variables required for an adequate morphological classification were blindly evaluated by four cytomorphologists in samples from 50 patients with myelodysplastic syndromes. The degree of agreement among observers was calculated using intraclass correlation coefficient and the generalized kappa statistic for multiple raters. The degree of agreement for the percentages of blasts in bone marrow and peripheral blood, ring sideroblasts in bone marrow, and erythroid, granulocytic and megakaryocytic dysplastic cells was strong (P<0.001 in all instances). After stratifying the percentages according to the categories required for the assignment of World Health Organization subtypes, the degree of agreement was not statistically significant for cases with 5-9% blasts in bone marrow (P=0.07), 0.1-1% blasts in peripheral blood (P=0.47), or percentage of erythroid dysplastic cells (P=0.49). Finally, the interobserver concordance for World Health Organization-defined subtypes showed a moderate overall agreement (P<0.001), the reproducibility being lower for cases with refractory anemia with excess of blasts type 1 (P=0.05) and refractory anemia with ring sideroblasts (P=0.09). In conclusion, the reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is acceptable but the defining criteria for blast cells and features of erythroid dysplasia need to be refined.
Collapse
Affiliation(s)
- Leonor Senent
- Servicio de Hematología, Hospital Universitario La Fe, Valencia, Spain.
| | | | | | | | | | | |
Collapse
|
13
|
Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Solé F, Marcos-Gragera R. Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): A population-based study, 1993–2007. Leuk Res 2012; 36:1262-6. [DOI: 10.1016/j.leukres.2012.06.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2012] [Revised: 06/04/2012] [Accepted: 06/14/2012] [Indexed: 11/16/2022]
|
14
|
Matarraz S, Teodosio C, Fernandez C, Albors M, Jara-Acevedo M, López A, Gonzalez-Gonzalez M, Gutierrez ML, Flores-Montero J, Cerveró C, Pizarro-Perea M, Garrastazul MP, Caballero G, Gutierrez O, Mendez GD, González-Silva M, Laranjeira P, Orfao A. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome. PLoS One 2012; 7:e44321. [PMID: 22952954 PMCID: PMC3432128 DOI: 10.1371/journal.pone.0044321] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Accepted: 08/01/2012] [Indexed: 12/22/2022] Open
Abstract
Myelodysplastic syndromes (MDS) are clonal stem cell disorders which frequently show a hypercellular dysplastic bone marrow (BM) associated with inefficient hematopoiesis and peripheral cytopenias due to increased apoptosis and maturation blockades. Currently, little is known about the role of cell proliferation in compensating for the BM failure syndrome and in determining patient outcome. Here, we analyzed the proliferation index (PI) of different compartments of BM hematopoietic cells in 106 MDS patients compared to both normal/reactive BM (n = 94) and acute myeloid leukemia (AML; n = 30 cases) using multiparameter flow cytometry. Our results show abnormally increased overall BM proliferation profiles in MDS which significantly differ between early/low-risk and advanced/high-risk cases. Early/low-risk patients showed increased proliferation of non-lymphoid CD34(+) precursors, maturing neutrophils and nucleated red blood cells (NRBC), while the PI of these compartments of BM precursors progressively fell below normal values towards AML levels in advanced/high-risk MDS. Decreased proliferation of non-lymphoid CD34(+) and NRBC precursors was significantly associated with adverse disease features, shorter overall survival (OS) and transformation to AML, both in the whole series and when low- and high-risk MDS patients were separately considered, the PI of NRBC emerging as the most powerful independent predictor for OS and progression to AML. In conclusion, assessment of the PI of NRBC, and potentially also of other compartments of BM precursors (e.g.: myeloid CD34(+) HPC), could significantly contribute to a better management of MDS.
Collapse
Affiliation(s)
- Sergio Matarraz
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Cristina Teodosio
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Carlos Fernandez
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Manuel Albors
- Servicio de Hematología, Hospital Juan Canalejo, La Coruña, Spain
| | - María Jara-Acevedo
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Antonio López
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - María Gonzalez-Gonzalez
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - María Laura Gutierrez
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Juan Flores-Montero
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Carlos Cerveró
- Servicio de Hematología, Hospital Virgen de la Luz, Cuenca, Spain
| | | | | | | | - Oliver Gutierrez
- Servicio de Hematología, Hospital Rio Hortega, Valladolid, Spain
| | - Guy Daniel Mendez
- Servicio de Hematología, Hospital de Jerez de la Frontera, Cádiz, Spain
| | | | - Paula Laranjeira
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Alberto Orfao
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
- * E-mail:
| |
Collapse
|
15
|
Breccia M, Federico V, Loglisci G, Salaroli A, Serrao A, Alimena G. Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes. Haematologica 2012; 96:e41-2. [PMID: 21972212 DOI: 10.3324/haematol.2011.048991] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
16
|
Santini V. The quest for the perfect MDS scoring system. Leuk Res 2011; 36:125-6. [PMID: 22154763 DOI: 10.1016/j.leukres.2011.10.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2011] [Revised: 10/26/2011] [Accepted: 10/29/2011] [Indexed: 10/14/2022]
|
17
|
Cazzola M, Della Porta MG, Travaglino E, Malcovati L. Classification and Prognostic Evaluation of Myelodysplastic Syndromes. Semin Oncol 2011; 38:627-34. [DOI: 10.1053/j.seminoncol.2011.04.007] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
18
|
Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011; 96:1433-40. [PMID: 21659359 DOI: 10.3324/haematol.2011.044602] [Citation(s) in RCA: 205] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Anemia is an established negative prognostic factor in myelodysplastic syndromes but the relationship between its degree and clinical outcome is poorly defined. We, therefore, studied the relationship between severity of anemia and outcome in myelodysplastic syndrome patients. DESIGN AND METHODS We studied 840 consecutive patients diagnosed with myelodysplastic syndromes at the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, and 504 patients seen at the Heinrich-Heine-University Hospital, Düsseldorf, Germany. Hemoglobin levels were monitored longitudinally and analyzed by means of time-dependent Cox's proportional hazards regression models. RESULTS Hemoglobin levels lower than 9 g/dL in males (HR 5.56, P=0.018) and 8 g/dL in females (HR=5.35, P=0.026) were independently related to reduced overall survival, higher risk of non-leukemic death and cardiac death (P<0.001). Severe anemia, defined as hemoglobin below these thresholds, was found to be as effective as transfusion-dependency in the prognostic assessment. After integrating this definition of severe anemia into the WHO classification-based Prognostic Scoring System, time-dependent regression and landmark analyses showed that the refined model was able to identify risk groups with different survivals at any time during follow up. CONCLUSIONS Accounting for severity of anemia through the WHO classification-based Prognostic Scoring System provides an objective criterion for prognostic assessment and implementation of risk-adapted treatment strategies in myelodysplastic syndrome patients.
Collapse
Affiliation(s)
- Luca Malcovati
- Department of Hematology Oncology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|